RenovoRx IncChange company Symbol lookupSelect an option...RNXT RenovoRx IncHOSZY Haci Omer Sabanci Holding ASFREJN Federal Home Loan Mortgage CorpNXPL NextPlat Corp$QCF E-MINI NASDAQ COMPOSITE SPOT FIXCURI CuriosityStream IncAXDX Accelerate Diagnostics IncMS-I Morgan StanleyTCRX TScan Therapeutics IncTRCK Track Group IncGo
Change company Symbol lookup
Select an option...
RNXT RenovoRx Inc
HOSZY Haci Omer Sabanci Holding AS
FREJN Federal Home Loan Mortgage Corp
NXPL NextPlat Corp
$QCF E-MINI NASDAQ COMPOSITE SPOT FIX
CURI CuriosityStream Inc
AXDX Accelerate Diagnostics Inc
MS-I Morgan Stanley
TCRX TScan Therapeutics Inc
TRCK Track Group Inc
Health Care : Biotechnology |
Company profileRenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in delivering its targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. Its first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial gemcitabine and RenovoCath. RenovoGem has been developed for the treatment of two rare diseases: pancreatic cancer and cholangiocarcinoma (CCA). It has completed the first of two planned interim analyses of the ongoing open-label Phase III TIGeR-PaC clinical trial.
|
|
|
|
| |
| Latest Earnings Missed Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 12, 2023 | -$0.36 | Q1 Consensus of 1 analysts | -$0.25 | Difference from consensus | -44.00% | Q2 Earnings will announce | (Unconfirmed) August 14, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
RNXT's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.